Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Transition Therapeutics
company
About
Transition Therapeutics is a biopharmaceutical company developing novel therapeutics for disease indications with large markets.
- 11 - 50
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $30.80M
- Industries
- Biopharma,Biotechnology,Therapeutics
- Founded date
- Jan 1, 1987
- Number Of Employee
- 11 - 50
- Operating Status
- Close
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 for the treatment of Alzheimer's disease and TT223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$30.80M
Transition Therapeutics has raised a total of
$30.80M
in funding over 2 rounds. Their latest funding was raised on
Jun 6, 2014 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 6, 2014 | Post-IPO Equity | $30.80M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Transition Therapeutics is funded by 1 investors.
Jack W. Schuler Living Trust
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
